0000000000367292

AUTHOR

Daniel Hartmann

0000-0003-4366-8986

showing 1 related works from this author

Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells.

2012

Alternatively polarized macrophages (Mϕ) shape the microenvironment of hepatocellular carcinoma (HCC) and temper anticancer immune responses. We investigated if sorafenib alters the HCC microenvironment by restoring classical macrophage polarization and triggering tumor-directed natural killer (NK) cell responses. In vivo experiments were conducted with sorafenib (25 mg/kg)-treated C57BL/6 wildtype as well as hepatitis B virus (HBV) and lymphotoxin transgenic mice with and without HCC. Monocyte-derived Mϕ or tumor-associated macrophages (TAM) isolated from HCC tissue were treated with sorafenib (0.07-5.0 μg/mL) and cocultured with autologous NK cells. Mϕ and NK cell activation was analyzed …

SorafenibNiacinamideCarcinoma Hepatocellularmedicine.medical_treatmentMacrophage polarizationDrug Evaluation PreclinicalAntineoplastic AgentsApoptosisBiologyMiceliver cancer; therapy; microenvironment; immunology; HCCmedicineAnimalsHumansneoplasmsHepatologyMacrophagesPhenylurea CompoundsLiver NeoplasmsDegranulationNF-kappa BInterleukinMacrophage ActivationSorafenibdigestive system diseasesKiller Cells NaturalMice Inbred C57BLCytokineLymphotoxinImmunologyCancer researchInterleukin 12CytokinesInterleukin 18medicine.drug
researchProduct